Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Gastroenterology Reports
Published in: Current Gastroenterology Reports 12/2017

01-12-2017 | Neurogastrointerology and Motility Disorders of the Gastrointestinal Tract (S Rao, Section Editor)

Medicinal Foods for Functional GI Disorders

Authors: Brent W. Acker, Brooks D. Cash

Published in: Current Gastroenterology Reports | Issue 12/2017

Login to get access

Abstract

Purpose of Review

Over the past 10 years, there has been a dramatic increase in basic and clinical research involving functional gastrointestinal disorders (FGIDs). New diagnostic and biomarker procedures are helping to identify physiologic disruptions associated with FGIDs on cellular and molecular levels. Simultaneously, clinicians are using new approaches to help manage patients with FGIDs. Among these, an important component of care has been the use of medical foods. These include probiotics, prebiotics, synbiotics, peppermint oil, caraway oil, curcumin, bovine immunoglobulin and many others.

Recent Findings

The putative effects of different medical foods make these therapies attractive for the management of FGIDs. These include effects on several pathophysiological mechanisms such as anti-inflammatory, smooth muscle relaxation, analgesia, mitigation of gut barrier dysfunction, and stimulation or inhibition of gastrointestinal receptors. Recent research has also demonstrated the efficacy of medical food products such as peppermint oil and serum-derived bovine immunoglobulin for the management of irritable bowel syndrome. Older data supports the probiotic VSL#3 and Bifidobacterium species. For functional dyspepsia, positive effects have been observed with the combination of caraway seed oil and peppermint oil as well as with STW-5, a botanical combination preparation, although robust RCTs are lacking.

Summary

With advancing knowledge regarding the pathogenesis of FGIDs, it is likely that the compounds available in the medical food category will increase dramatically, and they could play an important role in the management of several common and bothersome gastrointestinal conditions in the future.
Literature
1.
Weng W, Chen J. The eastern perspective on functional foods based on traditional Chinese medicine. Nutr Rev. 1996;54:S11–6.CrossRefPubMed
2.
Kamboj V. Herbal medicine. Curr Sci. 2000;78:35–9.
3.
Zhou S, Zhang S, Shen H, Chen W, Xu H, Chen X, et al. Curcumin inhibits cancer progression through regulating expression of microRNAs. Tumor Biol. 2017;39:1–12.
4.
Jiang S, Han J, Li T, Xin Z, Ma Z, Di W, et al. Curcumin as a potential protective compound against cardiac diseases. Pharmacol Res. 2017;119:373–83.CrossRefPubMed
5.
6.
Yang CS, Jin H, Guan F, Chen YK, Wang H. Cancer preventive activities of tea polyphenols. Molecules. 2016;21:1–19.
7.
Lee EA, Angka L, Rota SG, Hanlon T, Mitchell A, Hurren R, et al. Targeting mitochondria with avocatin B induces selective leukemia cell death. Cancer Res. 2015;75:2478–88.CrossRefPubMed
8.
•• Drossman DA. Functional gastrointestinal disorders: history, pathophysiology, clinical features, and Rome IV. Gastroenterology. 2016;150(6):1262–79. Updated clinical criteria and evidence review of the various functional gastrointestinal disorders. Key reading for a fuller understanding of the current approach to the diagnosis and management of these disorders. CrossRef
9.
Talley NJ. Functional gastrointestinal disorders as a public health problem. Neurogastroenterol Motil. 2008;20(s1):121–9.CrossRefPubMed
10.
Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol. 2012;10(7):712–21.CrossRefPubMed
11.
Mahadeva S, Ford AC. Clinical and epidemiological differences in functional dyspepsia between the East and the West. Neurogastroenterol Motil. 2016;28:167–74.CrossRefPubMed
12.
•• Burnett BP, Levy RM. Proposed industry nest practices in development and marketing of medical foods for the management of chronic conditions and diseases while awaiting regulation. Food Drug Law J. 2017;72:53–77. Excellent position paper on the current landscape of regulatory issues surrounding medical foods and the history of this class of therapies. PubMed
13.
14.
U.S. Department of Health and Human Services Food and Drug Administration Center for Food Safety and Applied Nutrition. Frequently asked questions about medical foods. Guidance for industry. 2nd ed. May 2016.
15.
De Geest S, Sabaté E. Adherence to long-term therapies: evidence for action. Eur J Cardiovasc Nurs. 2003;2(4):323.CrossRefPubMed
16.
17.
Linnaeus C. Species Plantarum. Stockholm. 2:1762–3.
18.
Hawthorn M, Ferrante J, Luchowski E, Rutledge A, Wei XY, Triggle DJ. The actions of peppermint oil and menthol on calcium channel dependent processes in intestinal, neuronal and cardiac preparations. Aliment Pharmacol Ther. 1988;2:101–18.CrossRefPubMed
19.
Goerg KJ, Spilker T. Effect of peppermint oil and caraway oil on gastrointestinal motility in healthy volunteers: a pharmacodynamic study using simultaneous determination of gastric and gall-bladder emptying and orocaecal transit time. Aliment Pharmacol Ther. 2003;17:445–51.CrossRefPubMed
20.
Harries N, James KC, Pugh WK. Antifoaming and carminative actions of volatile oils. J Clin Pharm Ther. 1977;2:171–7.CrossRef
21.
Galeotti N, Di Cesare ML, Mazzanti G, Bartolini A, Ghelardini C. Menthol: a natural analgesic compound. Neurosci Lett. 2002;322:145–8.CrossRefPubMed
22.
Hawrelak JA, Cattley T, Myers SP. Essential oils in the treatment of intestinal dysbiosis: a preliminary in vitro study. Altern Med Rev. 2009;14:380–4.PubMed
23.
Juergens UR, Stober M, Vetter H. The anti-inflammatory activity of L-menthol compared to mint oil in human monocytes in vitro: a novel perspective for its therapeutic use in inflammatory diseases. Eur J Med Res. 1998;3:539–45.PubMed
24.
Walstab J, Wohlfarth C, Hovius R, Schmitteckert S, Roth R, Lasitschka F, et al. Natural compounds boldine and menthol are antagonists of human 5-HT3 receptors: implications for treating gastrointestinal disorders. Neurogastroenterol Motil. 2014;26:810–20.CrossRefPubMed
25.
Khanna R, MacDonald JK, Levesque BG. Peppermint oil for the treatment of irritable bowel syndrome: a systematic review and meta-analysis. J Clin Gastroenterol. 2014;48:505–12.PubMed
26.
•• Cash BD, Epstein MS, Shah SM. A novel delivery system of peppermint oil is an effective therapy for irritable bowel syndrome symptoms. Dig Dis Sci. 2016;61:560–71. Important randomized controlled trial evaluating peppermint oil for IBS demonstrating improvements in multiple and global symptoms vs placebo. CrossRefPubMed
27.
Wilson D, Evans M, Weaver E, Shaw AL, Klein GL. Evaluation of serum-derived bovine immunoglobulin protein isolate in subjects with diarrhea-predominant irritable bowel syndrome. Clin Med Insights Gastroenterol. 2013;6:49–60.CrossRefPubMedPubMedCentral
28.
Valentin N, Camilleri M, Carlson P, Harrington SC, Eckert D, O’Neill J, et al. Potential mechanisms of effects of serum-derived bovine immunoglobulin/protein isolate therapy in patients with diarrhea-predominant irritable bowel syndrome. Physiol Rep. 2017;5(5):e13170.CrossRefPubMedPubMedCentral
29.
Brigidi P, Vitali B, Swennen E, Bazzocchi G, Matteuzzi D. Effects of probiotic administration upon the composition and enzymatic activity of human fecal microbiota in patients with irritable bowel syndrome of functional diarrhea. Res Microbiol. 2001;152:735–41.CrossRefPubMed
30.
Kim HJ, Camilleri M, McKinzie S, et al. A randomized control trial of a probiotic, VSL #3, on gut transit and symptoms in diarrhea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2003;17:895–904.CrossRefPubMed
31.
Kim HJ, Roque MI, Camilleri M, Lempke MB, Burton DD, Thomforde GM, et al. A randomized controlled trial of a probiotic combination VSL #3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterol Motil. 2005;17:687–96.CrossRefPubMed
32.
Mennigen R, Nolte K, Rijcken E, Utech M, Loeffler B, Senninger N, et al. Probiotic mixture VSL #3 protects the epithelial barrier by maintaining tight junction protein expression and preventing apoptosis in a murine model of colitis. Am J Physiol Gatrointest Liver Physiol. 2009;296(5):G1140–9.CrossRef
33.
Michail S, Kenche H. Gut microbiota is not modified by randomized, double-blind, placebo-controlled trial of VSL #3 in diarrhea-predominant irritable bowel syndrome. Probiotics Antimicrob Proteins. 2011;3(1):1–7.CrossRefPubMedPubMedCentral
34.
Wong RK, Yang C, Song GH, Wong J, Ho KY. Melatonin regulation as a possible mechanism for probiotic (VSL #3) in irritable bowel syndrome: a randomized double-blinded placebo study. Dig Dis Sci. 2015;60:186–94.CrossRefPubMed
35.
Walker MM, Alasdair W, Ung C, Talley NJ. The role of eosinophils and mast cells in intestinal functional disease. Curr Gastroenterol Rep. 2011;13:323–30.CrossRefPubMed
36.
Talley NJ, Fodor AA. Bugs, stool, and the irritable bowel syndrome: too much is as bad as too little? Gastroenterology. 2011;141:1555–9.CrossRefPubMed
37.
Hod K, Ringel Y. Probiotics in functional bowel disorders. Best Pract Res Clin Gastroenterol. 2016;30(1):89–97.CrossRefPubMed
38.
Curro D, Ianiro G, Pecere S, Bibbò S, Cammarota G, et al. Probiotics, fibre and herbal medicinal products for functional and inflammatory bowel disorders. Br J Pharmacol. 2016;174(11):1426–49.CrossRefPubMed
39.
May B, Kohler S, Schneider B. Efficacy and tolerability of a fixed combination of peppermint oil and caraway oil in patients suffering from functional dyspepsia. Aliment Pharmacol Ther. 2000;14:1671–7.CrossRefPubMed
40.
Coon TJ, Ernest E. Systematic review: herbal medicinal products for non-ulcer dyspepsia. Aliment Pharmacol Ther. 2002;16:1689–99.CrossRef
41.
Shams R, Oldfield EC, Copare J, Johnson DA. Peppermint oil: clinical uses in the treatment of gastrointestinal diseases. JSM Gastroenterol Hepatol. 2015;3(1):1035–46.
42.
Chey WD, Lacy BE, Cash BD, Epstein M, Shah S. Efficacy of caraway oil/l-menthol plus usual care vs placebo plus usual care, in functional dyspepsia patients with post-prandial distress (PDS) or epigastric pain (EPS) syndromes: results from a US RCT. Gastroenterology. 2017;152(5):S307.CrossRef
43.
Cremonini F. Standardized herbal treatments on functional bowel disorders: moving from putative mechanisms of action to controlled clinical trials. Neurogastroenterol Motil. 2014;26:893–900.CrossRefPubMed
44.
Sibaev A, Yuece B, Kelber O, Weiser D, Schirra J, Goke B, et al. STW5 (Iberogast) and its individual herbal components modulate intestinal electrophysiology of mice. Phytomedicine. 2006;13(Suppl 5):80–9.CrossRefPubMed
45.
•• von Arnim U, Peitz U, Vinson B, Gindermann KJ, Malfertheiner P. STW5, a phytopharmacon for patients with functional dyspepsia: results of a multicenter, placebo-controlled double-blind study. Am J Gastroenterol. 2007;102:1268–75. Large randomized controlled trial demonstrating efficacy for FD with STW-5 over 6 months compared to placebo. CrossRef
46.
Ottillinger B, Storr M, Malfertheiner P, Allescher HD. STW 5 (Iberogast)—a safe and effective standard in the treatment of functional gastrointestinal disorders. Wien Med Wochenschr. 2013;163:65–72.CrossRefPubMed
47.
Braden B, Caspary W, Borner N, Vinson B, Schneider AR. Clinical effects of STW5 (Iberogast) are not based on acceleration of gastric emptying in patients with functional dyspepsia and gastroparesis. Neurogastroenterol Motil. 2009;21(6):632–8.CrossRefPubMed
48.
Madisch A, Holtmann G, Plein K, Holtz J. Treatment of irritable bowel syndrome with herbal preparations: results of a double-blind, randomized, placebo-controlled, multicenter trial. Aliment Pharmacol Ther. 2004;19:271–9.CrossRefPubMed
Metadata
Title
Medicinal Foods for Functional GI Disorders
Authors
Brent W. Acker
Brooks D. Cash
Publication date
01-12-2017
Publisher
Springer US
Published in
Current Gastroenterology Reports / Issue 12/2017
Print ISSN: 1522-8037
Electronic ISSN: 1534-312X
DOI
https://doi.org/10.1007/s11894-017-0601-x

Other articles of this Issue 12/2017

Current Gastroenterology Reports 12/2017 Go to the issue

Nutrition and Obesity (S McClave and J Obert, Section Editors)

Popular Weight Loss Strategies: a Review of Four Weight Loss Techniques

Pediatric Gastroenterology (S Orenstein, Section Editor)

An Aerodigestive Approach to Laryngeal Clefts and Dysphagia Using Injection Laryngoplasty in Young Children

Nutrition and Obesity (S McClave and J Obert, Section Editors)

In Search of the Ideal Promotility Agent: Optimal Use of Currently Available Promotility Agents for Nutrition Therapy of the Critically Ill Patient

Nutrition and Obesity (S McClave and J Obert, Section Editors)

The Microbiome That Shapes Us: Can It Cause Obesity?

Nutrition and Obesity (S McClave and J Obert, Section Editors)

The Association Between Artificial Sweeteners and Obesity

Pediatric Gastroenterology (S Orenstein, Section Editor)

How to Care for Patients with EA-TEF: The Known and the Unknown
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits